Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- Author
- MAGNE TVEIT, Kjell1 2 ; GUREN, Tormod1 ; FOKSTUEN, Tone7 ; HANSEN, Flemming11 ; HOFSLI, Eva4 ; BIRKEMEYER, Elke5 ; JOHNSSON, Anders8 ; STARKHAMMAR, Hans9 ; YILMAZ, Mette Karen12 ; KELDSEN, Nina13 ; BERIT ERDAL, Anne1 ; DAJANI, Olav1 ; GLIMELIUS, Bengt6 7 ; DAHL, Olav3 ; CHRISTOFFERSEN, Thoralf2 ; PFEIFFER, Per10 ; SORBYE, Halfdan3 ; PYRHONEN, Seppo14 ; SIGURDSSON, Fridbjorn15 ; KURE, Elin1 ; IKDAHL, Tone1 ; SKOVLUND, Eva2
[1] Oslo University Hospital, Norway
[2] University of Oslo, Oslo, Norway
[3] Haukeland University Hospital and University of Bergen, Bergen, Norway
[4] St. Olavs Hospital, Trondheim, Norway
[5] Stavanger University Hospital, Stavanger, Norway
[6] Uppsala Hospital, Uppsala, Sweden
[7] Karolinska Institutet, Stockholm, Sweden
[8] Lund University Hospital, Lund, Sweden
[9] Linkoping University Hospital, Linkoping, Sweden
[10] Odense University Hospital, Odense, Denmark
[11] Aarhus University Hospital, Aarhus, Denmark
[12] Aalborg University Hospital, Aalborg, Denmark
[13] Herning Regional Hospital, Herning, Denmark
[14] Turku University Hospital, Turku, Finland
[15] National University Hospital, Reykjavik, Iceland - Source
Journal of clinical oncology. 2012, Vol 30, Num 15, pp 1755-1762, 8 p ; ref : 34 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- American Society of Clinical Oncology, Alexandria, VA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Cancer colorectal Cancérologie Chimiothérapie Cétuximab Essai clinique phase III Etude comparative Fluorouracil Folinate de calcium Métastase Oxaliplatine Stade avancé Traitement de première intention Anti-EGFR Agent alkylant Anticorps monoclonal Antimétabolite Cancer Dérivé de la fluoropyrimidine Dérivé de la pyrimidine Enzyme Inhibiteur enzyme Methyltransferases Pathologie de l'appareil digestif Pathologie de l'intestin Pathologie du côlon Pathologie du rectum Platine II Complexe Récepteur facteur croissance épiderme Thymidylate synthase Traitement Transferases Tumeur maligne
- Keyword (en)
- Antineoplastic agent Colorectal cancer Cancerology Chemotherapy Cetuximab Phase III trial Comparative study Fluorouracil Calcium folinate Metastasis Oxaliplatin Advanced stage First line treatment Alkylating agent Monoclonal antibody Antimetabolic Cancer Fluoropyrimidine derivatives Pyrimidine derivatives Enzyme Enzyme inhibitor Methyltransferases Digestive diseases Intestinal disease Colonic disease Rectal disease Platinum II Complexes Epidermal growth factor receptor Thymidylate synthase Treatment Transferases Malignant tumor
- Keyword (es)
- Anticanceroso Cancer de colon y recto Cancerología Quimioterapia Cetuximab Ensayo clínico fase III Estudio comparativo Fluorouracilo Folinato cálcico Metástasis Oxaliplatino Estadio avanzado Tratamiento de primera línea Agente alquilante Anticuerpo monoclonal Antimetabólito Cáncer Fluoropirimidina derivado Pirimidina derivado Enzima Inhibidor enzima Methyltransferases Aparato digestivo patología Intestino patología Colón patología Recto patología Platino II Complejo Receptor del factor de crecimiento epidérmico Thymidylate synthase Tratamiento Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13B Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / 002B13B01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 25894833
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2011.38.0915 
https://dx.doi.org/10.1200/JCO.2011.38.0915
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2011.38.0915\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:212:\"Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"1755\";s:8:\"\u0000*\u0000epage\";s:4:\"1762\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"MAGNE TVEIT\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Kjell\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:21:{i:0;s:13:\"GUREN, Tormod\";i:1;s:14:\"FOKSTUEN, Tone\";i:2;s:16:\"HANSEN, Flemming\";i:3;s:11:\"HOFSLI, Eva\";i:4;s:16:\"BIRKEMEYER, Elke\";i:5;s:16:\"JOHNSSON, Anders\";i:6;s:17:\"STARKHAMMAR, Hans\";i:7;s:19:\"YILMAZ, Mette Karen\";i:8;s:13:\"KELDSEN, Nina\";i:9;s:17:\"BERIT ERDAL, Anne\";i:10;s:12:\"DAJANI, Olav\";i:11;s:16:\"GLIMELIUS, Bengt\";i:12;s:10:\"DAHL, Olav\";i:13;s:23:\"CHRISTOFFERSEN, Thoralf\";i:14;s:13:\"PFEIFFER, Per\";i:15;s:15:\"SORBYE, Halfdan\";i:16;s:15:\"PYRHONEN, Seppo\";i:17;s:21:\"SIGURDSSON, Fridbjorn\";i:18;s:10:\"KURE, Elin\";i:19;s:12:\"IKDAHL, Tone\";i:20;s:13:\"SKOVLUND, Eva\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:212:\"Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2011.38.0915\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:212:\"Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"1755\";s:8:\"\u0000*\u0000epage\";s:4:\"1762\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"MAGNE TVEIT\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Kjell\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:21:{i:0;s:13:\"GUREN, Tormod\";i:1;s:14:\"FOKSTUEN, Tone\";i:2;s:16:\"HANSEN, Flemming\";i:3;s:11:\"HOFSLI, Eva\";i:4;s:16:\"BIRKEMEYER, Elke\";i:5;s:16:\"JOHNSSON, Anders\";i:6;s:17:\"STARKHAMMAR, Hans\";i:7;s:19:\"YILMAZ, Mette Karen\";i:8;s:13:\"KELDSEN, Nina\";i:9;s:17:\"BERIT ERDAL, Anne\";i:10;s:12:\"DAJANI, Olav\";i:11;s:16:\"GLIMELIUS, Bengt\";i:12;s:10:\"DAHL, Olav\";i:13;s:23:\"CHRISTOFFERSEN, Thoralf\";i:14;s:13:\"PFEIFFER, Per\";i:15;s:15:\"SORBYE, Halfdan\";i:16;s:15:\"PYRHONEN, Seppo\";i:17;s:21:\"SIGURDSSON, Fridbjorn\";i:18;s:10:\"KURE, Elin\";i:19;s:12:\"IKDAHL, Tone\";i:20;s:13:\"SKOVLUND, Eva\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:212:\"Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2011.38.0915\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2011.38.0915\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:212:\"Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"1755\";s:8:\"\u0000*\u0000epage\";s:4:\"1762\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"MAGNE TVEIT\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Kjell\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:21:{i:0;s:13:\"GUREN, Tormod\";i:1;s:14:\"FOKSTUEN, Tone\";i:2;s:16:\"HANSEN, Flemming\";i:3;s:11:\"HOFSLI, Eva\";i:4;s:16:\"BIRKEMEYER, Elke\";i:5;s:16:\"JOHNSSON, Anders\";i:6;s:17:\"STARKHAMMAR, Hans\";i:7;s:19:\"YILMAZ, Mette Karen\";i:8;s:13:\"KELDSEN, Nina\";i:9;s:17:\"BERIT ERDAL, Anne\";i:10;s:12:\"DAJANI, Olav\";i:11;s:16:\"GLIMELIUS, Bengt\";i:12;s:10:\"DAHL, Olav\";i:13;s:23:\"CHRISTOFFERSEN, Thoralf\";i:14;s:13:\"PFEIFFER, Per\";i:15;s:15:\"SORBYE, Halfdan\";i:16;s:15:\"PYRHONEN, Seppo\";i:17;s:21:\"SIGURDSSON, Fridbjorn\";i:18;s:10:\"KURE, Elin\";i:19;s:12:\"IKDAHL, Tone\";i:20;s:13:\"SKOVLUND, Eva\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:212:\"Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2011.38.0915\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:212:\"Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"1755\";s:8:\"\u0000*\u0000epage\";s:4:\"1762\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"MAGNE TVEIT\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Kjell\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:21:{i:0;s:13:\"GUREN, Tormod\";i:1;s:14:\"FOKSTUEN, Tone\";i:2;s:16:\"HANSEN, Flemming\";i:3;s:11:\"HOFSLI, Eva\";i:4;s:16:\"BIRKEMEYER, Elke\";i:5;s:16:\"JOHNSSON, Anders\";i:6;s:17:\"STARKHAMMAR, Hans\";i:7;s:19:\"YILMAZ, Mette Karen\";i:8;s:13:\"KELDSEN, Nina\";i:9;s:17:\"BERIT ERDAL, Anne\";i:10;s:12:\"DAJANI, Olav\";i:11;s:16:\"GLIMELIUS, Bengt\";i:12;s:10:\"DAHL, Olav\";i:13;s:23:\"CHRISTOFFERSEN, Thoralf\";i:14;s:13:\"PFEIFFER, Per\";i:15;s:15:\"SORBYE, Halfdan\";i:16;s:15:\"PYRHONEN, Seppo\";i:17;s:21:\"SIGURDSSON, Fridbjorn\";i:18;s:10:\"KURE, Elin\";i:19;s:12:\"IKDAHL, Tone\";i:20;s:13:\"SKOVLUND, Eva\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:212:\"Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2011.38.0915\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:212:\"Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"1755\";s:8:\"\u0000*\u0000epage\";s:4:\"1762\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"MAGNE TVEIT\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Kjell\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:21:{i:0;s:13:\"GUREN, Tormod\";i:1;s:14:\"FOKSTUEN, Tone\";i:2;s:16:\"HANSEN, Flemming\";i:3;s:11:\"HOFSLI, Eva\";i:4;s:16:\"BIRKEMEYER, Elke\";i:5;s:16:\"JOHNSSON, Anders\";i:6;s:17:\"STARKHAMMAR, Hans\";i:7;s:19:\"YILMAZ, Mette Karen\";i:8;s:13:\"KELDSEN, Nina\";i:9;s:17:\"BERIT ERDAL, Anne\";i:10;s:12:\"DAJANI, Olav\";i:11;s:16:\"GLIMELIUS, Bengt\";i:12;s:10:\"DAHL, Olav\";i:13;s:23:\"CHRISTOFFERSEN, Thoralf\";i:14;s:13:\"PFEIFFER, Per\";i:15;s:15:\"SORBYE, Halfdan\";i:16;s:15:\"PYRHONEN, Seppo\";i:17;s:21:\"SIGURDSSON, Fridbjorn\";i:18;s:10:\"KURE, Elin\";i:19;s:12:\"IKDAHL, Tone\";i:20;s:13:\"SKOVLUND, Eva\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:212:\"Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
